# A Study of GC101 TIL in Advanced Melanoma (BZ)

> **NCT06120712** · PHASE1,PHASE2 · COMPLETED · sponsor: **Shanghai Juncell Therapeutics** · enrollment: 18 (actual)

## Conditions studied

- Tumor Infiltrating Lymphocytes
- Safety
- Melanoma
- Efficacy
- Adverse Drug Event

## Interventions

- **BIOLOGICAL:** GC101 TIL

## Key facts

- **NCT ID:** NCT06120712
- **Lead sponsor:** Shanghai Juncell Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-08
- **Primary completion:** 2024-11-12
- **Final completion:** 2025-11-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06120712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06120712, "A Study of GC101 TIL in Advanced Melanoma (BZ)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06120712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*